Peroxisome proliferator-activated receptors (PPARs) belong to a ligand-dependent nuclear receptor family. In the past decade, numerous studies have revealed the presence and significance of PPARs in the reproductive system. PPARs are expressed at different levels of hypothalamic-pituitary-gonadal (HPG) axis. They are also present in the uterus as well as in the placenta and embryonic tissues of different species. PPARs significance has been reported during the estrous/menstrual cycle and pregnancy with the gamma isoform studied most frequently. Several studies indicate that PPARs regulate proliferation of ovarian cells, tissue remodeling and steroidogenesis. In the endometrium, PPARs are engaged in the regulation of prostaglandins, steroids and cytokines synthesis. The role of PPARs in the trophoblast differentiation, maturation and invasion as well as in the embryo development has also been demonstrated. In this review, we summarize current findings concerning the role of PPARs in the regulation of reproductive functions at different levels of the HPG axis during various physiological statuses of females. In addition, the role of PPARs in the modulation of uterine functions as well as the placenta and embryo development has also been discussed.
Introduction
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family which belong to the steroid receptor superfamily. To date, three subtypes of these receptors, encoded by distinct genes, have been described as PPARa, PPARb (named also PPARd) and PPARg [1] [2] [3] . Moreover, three variants of PPARg, created by alternative promoter usage and splicing, have been characterized as g1, g2 and g3 [4] .
PPARs create a structure typical for nuclear receptors and their activation requires heterodimerization with another nuclear receptor, 9-cis retinoic acid receptor (RXR). The heterodimer binds afterwards to a specific DNA sequence -peroxisome proliferator response element (PPRE), and activates transcription of various target genes. PPARs are modulated by numerous cofactors that enhance (as co-activators) or reduce (as co-inhibitors) their activity [5] .
PPARs are ligand-dependent structures that are activated by natural and synthetic compounds. PPARs can also be activated in the absence of the ligand or by alternative pathways like the phosphorylation. Natural activators comprise unsaturated fatty acids, eicosanoids, prostaglandin (PG)-related compounds or oxidized lipids while a large group of synthetic ligands includes hypolipidemic drugs (fibrates), anti-inflammatory (e.g. indomethacin and fenoprofen) or insulin-sensitizing drugs (thiazolidinediones, TZDs) [6] . Moreover, a treatment with TZDs improves fertility through an induction of ovulation in women with polycystic ovary syndrome (PCOS) [8] .
The presence of all PPAR isoforms has been found in various female reproductive tissues in different species. Experiments with knockout rodents suggest the role of PPARs in the regulation of reproductive functions. An inactivation of PPARg indicated serious consequences that lead to the death of mouse embryo at an early stage of development [9] . PPARb-null mice showed abnormalities in placenta development that increased embryos mortality [10] . The administration of the specific PPARb agonist reversed the implantation disorders in rats and it even increased the number of implanted embryos compared with the control group [11] . Rodents lacking PPARa displayed a higher risk of maternal abortion and neonatal mortality [12] . In this review we attempt to summarize present knowledge and discuss the results on the role of PPARs in the regulation of reproductive functions in females.
PPARs and the hypothalamic--pituitary (HP) axis
The expression of PPAR isoforms has been detected in mouse, ovine and human pituitary gland [13, 14] and in rodent hypothalamus [15] , but their significance in the regulation of reproductive functions at the level of hypothalamic-pituitary (HP) remains poorly understood. It has been demonstrated that PPARg activation by TZDs inhibited the development of pituitary adenomas in mice and humans [18, 19] but did not affect the secretion of prolactin (PRL), follicle-stimulating hormone (FSH) or luteinizing hormone (LH) by ovine pituitary or LH by murine LbetaT2 gonadotrophic pituitary tumor cell line [16] . However, recent data indicate a direct role for PPARg in the modulation of pituitary function [18] . Rosiglitazone suppressed GnRH-mediated induction of LH and FSH genes expression and a conditional knockout of PPARg in pituitary gonadotrophs caused an increase in LH levels in female mice and reduced litter size [18] . The presented above data suggest the involvement of PPARs in the regulation of reproductive processes at the HP axis but this knowledge is too narrow to define its specific role.
PPARs in the ovary
All PPAR isoforms are expressed in ovaries of different species including rodent, sheep, cow, pig, rabbit, buffalo and human [14, [19] [20] [21] but the role of gamma isoform has been studied most extensively compared with two other forms. Many studies have shown that PPARs gene and/or protein expression varies depending on ovarian cell type, physiological status and the species [14, [22] [23] [24] [25] [26] . It has also been frequently reported that PPARs are engaged in the regulation of various ovarian functions. A tissue-specific deletion of PPARg in mouse ovary markedly reduced fertility [19] . Although these mice had a normal number of follicles and developed corpora lutea, progesterone (P 4 ) level was reduced, implantation rates were lower and litters were smaller [19] . An administration of PPARg agonist for 4 weeks did not affect folliculogenesis, but increased plasma P 4 concentration [27] . There is a lack of similar studies on the tissue-specific deletion of the two remaining PPAR isoforms.
PPARs and remodeling of the ovarian tissue
It has been demonstrated that PPARg modulates follicular development, oocyte maturation, ovulation and the CL formation or regression [22, 28] . These effects are mediated by the regulation of several genes controlling angiogenesis, inflammatory response, apoptosis and cell cycle. It was suggested that PPARg may be involved in ovulation and luteinization by inhibiting the secretion of pro-inflammatory cytokines such as tumor necrosis factor (TNF) a and interleukin (IL)-6 in human granulosa-lutein cells [29] . In ovarian macrophages, inducible nitric oxide synthase (NOS2), an important pro-inflammatory enzyme that regulates ovulation, was also reduced after treatment with PPARg agonist [30] .
There is evidence that PPARg activation affected the proliferation of ovine granulosa cells but showed no impact on the apoptotic markers [14] . In turn, in rodent luteal and granulosa cells vitality was modulated by the regulation of anti-apoptotic bcl-2 protein and tumor suppressor p53 expression [31, 32] . PPARs may affect the expression and activity of proteases and angiogenic factors which are engaged in the tissue remodeling and the formation of follicular or luteal cells. Although the interaction between PPARs and matrix metalloproteinases (MMP-3, -9, -13), plasminogen activators, vascular endothelial growth factor (VEGF) and its receptors (Flt-1, Flt-2) as well [22, 33] , the existence of such association in ovarian tissue needs confirmation.
PPARs and steroidogenesis
PPARs appear to be important regulators of steroid (P 4 and E 2 ) production. It has been frequently reported that activators of PPARg regulate steroidogenesis in follicular cells of different species but the available results are contradictory. Stimulatory effect of synthetic or natural activators of PPARg on P 4 secretion was noted in mixed culture of human stromal, theca and granulosa cells [34] , rat granulosa cells [35] , ovine granulosa cells [14] , porcine theca cells [20] and porcine follicles [36] . In turn, a lack of changes in P 4 or E 2 production was observed in human granulosa-lutein cells [29] . There are also studies showing an inhibitory effect of PPARg activators on P 4 production by cultured porcine and human LH-stimulated granulosa cells [37, 38] . Recent data showed that the activation of PPARa and PPARg affected steroidogenesis and follicle development in mouse preantral follicles treated with tumor necrosis factor alpha (TNFa), used as a model for studying follicle development in patients with PCOS [39] . Moreover, polymorphism in PPARg gene is associated with metabolic disorders and abnormal blood E 2 concentration in PCOS patients [40, 41] .
There is a limited amount of studies showing the effect of PPARs activation on steroidogenesis in luteal cells. PPARg agonists enhanced P 4 production in bovine luteal cells collected during mid-luteal phase of the estrous cycle [42] or by corpora lutea explants of pseudopregnant rabbits [21] . However, there was no effect of PPARg ligands on P 4 production in hemisected and cultured rat CL [32] . Our recent results indicate that PPAR (a, b, g) activators reduced P 4 secretion by the CL explants during early stages (days 10-12 and 14-16) of pregnancy, whereas they were ineffective during the corresponding days of the estrous cycle [43] . Moreover, PPARa agonist diminished E 2 secretion by the CL explants collected during midand late-luteal phases of the estrous cycle and early pregnancy while natural or synthetic PPARg ligands did not affect E 2 release. In turn, PPARb activation inhibited E 2 release by the CL during early pregnancy, but did not affect the secretion during luteal phase of the estrous cycle [43] . The effect of PPAR ligands on steroidogenesis can be mediated by a modulation of steroidogenic enzymes action. However, inconsistency in their expression and activity has been often demonstrated by researchers. For instance, a stimulatory effect of PPARg activation on steroidogenesis can be mediated by up-regulation of steroidogenic acute regulatory (StAR) protein in human and macaque granulosa cells [44, 45] or by 3b-HSD in porcine ovarian follicles [36] . An opposite effect of PPARg ligands on 3b-HSD expression and P 4 release was observed in porcine granulosa cells [37] . There are also studies showing that PPARg or PPARa activation inhibited aromatase expression in human granulosa cells and mouse ovary [46, 47] . Different studies, including ours, indicate that changes in steroids production evoked by PPAR ligands are not always followed by alternations in genes or proteins expression of 3b-HSD in porcine endometrium and ovine granulosa cells [14, 43] , CYP11A1 in ovine granulosa cells [14] or CYP17 in porcine theca cells [20] . The discrepancies in steroids production or expression of enzymes responsible for steroids synthesis could be a result of differences in species, ovarian cells type, physiological status, type and dose of PPAR ligands, time of the tissue incubation with the treatments.
The above results revealed that PPARs are engaged in the regulation of various ovarian functions in different species. They also suggest a different receptivity of the tissue to PPAR agonists depending on physiological status of individuals. However, molecular mechanisms of PPARs, especially alpha and beta isoforms, action in the ovary still remains not fully understood. Because certain PPAR ligands are clinically used to treat diabetes or polycystic ovary syndrome (PCOS), the understanding of their exact role in the ovary should be an important reason of interest.
PPARs in the uterus
Compared to the research on PPARs in the ovary, the studies on their functions in the uterus are limited. Most experiments were carried out in the endometrium, where several essential events occur intended for preparation of the tissue to the embryo implantation, placentation and pregnancy sustain. The expression of all PPAR isoforms has been demonstrated in human, bovine, ovine, porcine and rodent endometrial tissue [48] [49] [50] .
Previously published data indicate that PPARa and PPARb expression markedly increased in rodent endometrial stroma at the beginning of implantation [50] while PPARg mRNA level was higher during fertilization but declined at the beginning of implantation [50] . In the endometrium of pregnant cows, a lack of differences in PPARg mRNA level was noted [51] , while in ovine endometrium the expression of PPARb stayed at a constant level on days 7-17 (peri-implantation period), PPARg declined from days 7 to 17 and PPARg peaked www.fhc.viamedica.pl first at day 9 and then on day 17 [49] . Differences in PPARb and PPARg gene expression were also reported in porcine endometrium [52] . A higher expression of PPARb was reported on day 15 of the estrous cycle (during luteolysis) compared with days 15 and 25 of pregnancy (peri-implantation period). In turn, the transcript level of PPARg was elevated during the tested days of pregnancy compared with the level on day 15 of the estrous cycle [52] . The results of our studies [26] showed increased mRNA levels of PPARa and PPARb during the luteal phase compared with the follicular phase of the estrous cycle. During pregnancy, the decreased PPARa and PPARb mRNA levels were noted on days 11-12 (the time of maternal recognition of pregnancy) and higher on days 13-15, at the beginning of implantation. In turn, the PPARg gene expression was higher on days 13-15 of the estrous cycle (during luteolysis) than on the remaining days while during pregnancy the transcript level was increased on days 16-30 of pregnancy (peri-implantation period) compared with days 5-15 [26] . In another experiment performed on gilts subjected to surgical procedures, we reported markedly increased mRNA levels of PPARa and PPARb, but not PPARg, in the endometrium collected from the uterine horn with fetuses on day 14 of pregnancy compared to the horn without embryos [53] .
The above results have shown that uteri of different mammal species express all PPAR isoforms. The discrepancy in their expression pattern, which was often reported, can be related to physiological status of individuals or species. Differential PPARs expression profile during various reproductive conditions suggest their involvement in the regulation of uterine secretory function which can be crucial for luteolysis of the CL during the estrous cycle or the embryo implantation during pregnancy. PPARs effect at the endometrial level can be mediated by a number of ways.
Interactions between PPARs and prostaglandins (PGs)
The endometrial tissue is a place where PPARs can regulate the expression and activity of prostaglandin endoperoxidase synthase 2 (PTGS2, COX-2, PTGH) -a rate-limiting enzyme responsible for PGs synthesis. Endometrial PTGS-derived PGF 2a and PGE 2 are crucial in the regulation of the CL activity through respective luteolytic or luteotrophic actions in various species [54, 55] . PGs significance has been highlighted in the regulation of ovulation, the CL functions, maternal recognition of pregnancy, implantation and parturition [56] . Recently, the role of PTGS-derived PGI 2 (prostacyclin) has been reported in the regulation of blastocyst development, embryo hatching and the implantation course in mice and pigs [57, 58] .
It has been suggested that there is a direct interaction between PGs and PPARs, because PPAR response element was identified in the PTGS2 gene promoter [59] and the activation of PPARs affected PTGS2 expression in various cell or tissue types including human [60] and bovine endometrial cells [48, 61] , WISH cells line and primary amnion cells [62] . The administration of different PPARb agonists to the PTGS2 deficient mice restored reduced implantation rates what indicates a direct interaction between these pathways [63] . In addition, the treatment of bovine endometrial cells with PPARa and PPARb activators enhanced both PGE 2 and PGF 2a production [48] . Our studies showed that PPARa, PPARb and PPARg agonists stimulated PGF 2a secretion by porcine endometrium during mid-and late-luteal phase of the estrous cycle whereas the ligands were less effective during the corresponding days of pregnancy. In addition, the tested PPAR agonists did not affect PGFS gene expression during luteal phase of the estrous cycle, but they modulated the enzyme mRNA level during peri-implantation [64] . This suggests different sensitivity of porcine endometrium to PPAR ligands associated with the physiological status of animals.
We have recently reported that PPARs are mediators of PGE 2 production in the porcine endometrium during the luteal phase of the estrous cycle and the time of peri-implantation. Ligands of PPARg or PPARb enhanced both the synthesis and accumulation of PGE 2 in culture media depending on the phase of the estrous cycle or pregnancy, whereas PPARα ligands were less effective in PGE 2 production [65] .
As mentioned before, PPARs can interact with PGI 2 and certain PGI 2 analogues can act as ligands for the PPARb. This ability suggests that the effects of PGI 2 may be mediated by PPARb in mouse, rat and sheep uterus [49, 66, 67 ]. An interaction between PGI 2 and PPARb facilitated implantation in mouse by increasing the number of implanted embryos [63] . It has been recently reported that PGI 2 -induced PPARb activation accelerated blastocyst hatching in mice [57] and a deletion of PPARb at early stages of preimplantation of mouse embryos caused a delay of blastocyst hatching.
Interactions between PPARs and steroids
Apparently, steroids (P 4 and E 2 ) are crucial regulators of architectonical alterations in the uterine structures. They regulate cell proliferation, differentiation and remodeling of various uterine cell types depending on the female physiological status [68] . The CL is the main source of steroid hormones in the uterine tissue, www.fhc.viamedica.pl although steroidogenic activity of the endometrium has been also reported [69] . There are available data documenting a possible interaction between steroids and PPARs in the uterus. PPARg activation increased mouse uterine mass, proliferation and evoked morphogenetic alterations in the tissue [70] . PPARs can bind to the estrogen response element (ERE) in targeted genes and act as a regulator of the estrogen receptor (ER) expression [71] . There is evidence that PPARa or PPARg activation affected the protein level of ERg in all mouse uterine compartments [70] . It has been suggested that PPARg activation increases proliferative estrogen action and facilitates estrogen-dependent endometrial hyperplasia but PPARa activation has an opposite effect -attenuates estradiol impact on the uterus by reducing cell proliferative capacity [70] .
PPARs can also be engaged in steroids synthesis in the endometrial tissue. Our unpublished results suggest that the receptors can mediate P 4 and E 2 production in porcine endometrial explants depending on the physiological status of animals. For instance, an inhibitory effect of PPAR (a, b, g isoforms) agonists on P 4 release was noted during mid-luteal phase of the estrous cycle but not in late-luteal phase. In addition, PPARa and PPARg agonists reduced E 2 secretion during early pregnancy while PPARb and PPARg activation increased the secretion during luteal phase of the estrous cycle.
Interactions between PPARs and cytokines
It has been frequently reported, that cytokines, mediators of immune response, are important regulators of reproductive functions. Their significance has been described during the estrous/menstrual cycle, but majority of the studies focused on their role during implantation, when the regulation of maternal immune response to an antigenically different embryo is required. The endometrium secretes a number of cytokines such as IL-1, IL-6, leukemia inhibitory factor (LIF), colony stimulating factor 1 (CSF-1), TNFa [72] . They are engaged in the preparation of endometrium for the embryo implantation, PGs synthesis, trophoblast elongation, placenta development and pregnancy maintenance [69, 73] . Uterine disorders such as inflammation, adenomyosis, endometriosis are accompanied by altered number of cells synthetizing cytokines and an unbalanced amount of secreted cytokines [74, 75] .
Interactions between PPARs and cytokines have been frequently suggested though most researchers described PPARs as significant immunomodulators in non-reproductive cells or tissues [76] . Only two groups of researchers reported that PPARg ligands modulated the secretion of IL-1, IL-6, IL-8 or colony stimulating factor-1 (CSF-1) by human endometrial cells [77, 78] . Contrary, a modulatory effect of cytokines on PPARs activity has also been reported. The results of our studies indicate that IL-6 and interferon g (IFNg) had an impact on PPARs gene expression in the porcine endometrium on day 14 of the estrous cycle or pregnancy [79] . We demonstrated a very weak effect of the cytokines during the estrous cycle, but a strong effect during pregnancy. IFNg affected the expression of all PPAR isoforms while IL-6 influenced only PPARg gene expression [79] .
There are some reports suggesting that PPARg plays an important role in the regulation of inflammatory processes in the endometrium [80] and the inhibition of the immune response expressed by a decreased synthesis of IL-6 and IL-8 could be effectively used to treat endometriosis in women [78] . Further research is required to find out whether PPARs are involved in the regulation the synthesis of cytokines -factors that modulate mother's immune response during early pregnancy (physiological state) and if they are an important link in the course of inflammatory processes in the female reproductive system (pathological state).
PPARs in the placenta
Human and animal studies have shown that PPARs play a regulatory role in placental development and functions [81] [82] [83] . Three isoforms of PPARs have been detected in placentas of a limited number of species including mouse, rat, ovine and human [49, 84, 85] . Recently, PPARg expression has been also confirmed in bovine throphoblast [86] . Depending on the species and pregnancy stage, PPARs display a different expression in diverse compartments of the placenta [82, 87, 88] .
It has been frequently reported that the principal role in human and rodent placenta development is played by PPARg. In rodents, the role of PPARg in trophoblast differentiation, maturation and invasion seems to be established. PPARg expression in rat placenta was high on day 13, during placental differentiation and maturation, and later significantly declined [85] . In addition, oral administration of PPARg ligand enhanced PPARg transcript level in the rat placenta and decreased embryos mortality by half [85] . Mice lacking this isoform (PPARg -/-) die on day 10 of gestation due to the defects in trophoblast differentiation, placental vascularization and nutritional transport to the developing embryos [89] . Recent reports indicate that in fully viable PPARg-null mice, obtained through specific and total epiblastic gene deletion, the placental vasculature defects, which www.fhc.viamedica.pl are associated with unbalanced expression of pro-and antiangiogenic factors, might be a major reason of embryonic lethality [90] . In the same study the authors indicated that PPARg activation affected mouse placental microvasculature and the layers organization by the regulation of proangiogenic genes expression such as proliferin (PLF), vascular endothelial growth factor (VEGF) and platelet-endothelial cell adhesion molecule-1 (Pecam1) [90] . PPARg affects rodent trophoblast differentiation by interaction with various coactivators such as PPAR-binding protein (PBP) and PPAR-interacting protein (PRIP) [91] . In addition, the important role of PPARg in placental development depends on the expression of anti-adhesive molecule Muc1, which is expressed in placenta, but not in other tissues such as adipocytes [92] .
In humans, the role of PPARg in placental development is less clear and the results of mainly in vitro experiments have not been always consistent. Available data indicate that PPARg activation modulates the differentiation of cytotrophoblast into syncytiotrophoblast [93] . It has been also suggested that PPARg-dependent trophoblast differentiation process is mediated by the increase of chorionic gonadotropin beta-subunit (hCGb, biochemical marker of trophoblast differentiation) expression and secretion as well as by the synthesis of human placental lactogen (hPL), human placental growth hormone (hPGH) and leptin [93] . Interestingly, whereas the exposure of cultured primary trophoblasts to synthetic PPARg ligand enhanced trophoblast differentiation, the natural ligand had opposite effect and promoted trophoblast apoptosis through p53 up-regulation [94] .
PPARg plays an important role in the trophoblast invasion. Tarrade et al. [95] reported that PPARg is highly expressed in human cytotrophoblasts at the feto-maternal interface, particularly in the extravillous cytotrophoblasts involved in uterus invasion. They also showed that both synthetic and natural PPARg agonists inhibited extravillous cytotrophoblast invasion and the treatment with PPARg antagonist facilitated the invasion process [95] . Recently, the analysis of PPARg-target genes in human trophoblast led to characterization of new factors engaged in the regulation of trophoblast invasion [82, 83, 96] . Among those, heme-oxygenase-1 (HO-1), human placental growth hormone (hPGH), the pregnancy-associated plasma protein (PAPP-A) and hCG seems to have a significant role in this process [97] [98] [99] . Moreover, the role of PPARs in the immune response and immunotolerance during trophoblast invasion cannot be neglected [100] . Indeed, there is evidence showing PPARg-dependent inhibition of the production of cytokines such as IL-1b, IL-6, IL-8, IL-10 and TNFa in human placenta as well as in amnion and choriodecidua [101] . An important relationship between cytokines and PPARs can be suggested during the beginning of parturition when an increased production of pro-inflammatory cytokines [102] correlates with changes in PPARs expression in human placental tissues [88] .
One should also not disregard the importance of PPARg in the regulation of placental lipid homeostasis even if available data are limited. Transfer of fatty acids from the mother to the fetus is absolutely necessary for a proper embryo development, implantation, placenta development, and pregnancy maintenance [103, 104] . Various proteins engaged in fatty acid binding, transport, b-oxidation and lipid accumulation are expressed in the placental tissue [105] . It has been suggested that the absence of PPARg or PPARb might lead to the defects of placenta and fetus development due to an impaired placental/fetal fatty acid homeostasis [10] . The activation of PPARg regulates fatty acid uptake and lipid storage in primary human trophoblasts. This effect was characterized by an increased expression of genes encoding fatty acid transporters (FATP1 and FATP2) and a fat droplet associated protein, adipophilin [81, 106] . There are also reports suggesting a possible role of PPARs in the regulation of proteins involved in placental fatty acid/lipids metabolism such as cytochrome P450 4A (CYP4A), cyclooxygenases and lipooxygenases (LOX) [105] .
Although the role of PPARg in placental development is significant and unquestionable, there is evidence that PPARb can also be an important player in this process. As mentioned before, a lack of PPARα in the rodent model resulted in severe placenta defects caused mainly by the loss of connection between the placenta and decidua [10] . In comparison to wild-type animals PPARb -/-pregnant mice exhibited smaller placental labyrinth, maternal bleeding to the labyrinth and increased fetal mortality [10] . PPARb is involved in trophoblast growth by regulating differentiation of trophoblast giant cells via PI3K/Akt pathway that is important in the blastocyst implantation, alteration of the maternal decidua structure and secretion of hormones such as placental lactogens I and II (PL-I, PL-II) and proliferin [107] .
While the role of PPARg in trophoblast differentiation, invasion and placental functions have been extensively studied in human and rodent models, the involvement of other PPAR isoforms has not been not fully explained. In addition, most studies have only been performed in humans and rodents having invasive placentas. Therefore, it is reasonable to conduct similar studies in mammals with non-invasive placentas, occurring in domestic animals such as pigs, cows and 
PPARs in the embryo
The expression of all PPARs has been found in bovine, human and mouse embryos [108, 109] . PPARb '-' -lack of data concerning PPARs effect on reproductive tissues; COX -cyclooxygenases; CSF-1 -colony stimulating factor 1; CYP4A -cytochrome P450 4A; E 2 -estradiol; FATP -fatty acid transporters; Flt -fms-related tyrosine kinase; angiopoietin-like 4 protein; FSHfollicle-stimulating hormone; hCG -human chorionic gonadotropin; HO-1 -heme-oxygenase-1; hPGH -human placental growth hormone; IL -interleukin; LH -luteinizing hormone; LOX -lipooxygenases; MMP -matrix metalloproteinase; P 4 -progesterone; PAPP-A -the pregnancy-associated plasma protein; PBP -PPAR-binding protein; Pecam1 -platelet/endothelial cell adhesion molecule 1; PGE 2 -prostaglandin E 2 ; PGF 2a -prostaglandin F 2a ; PGI 2 -prostaglandin I 2 /prostacyclin; PI3K/Akt -phosphatidylinositol-3 kinase/RAC-alpha serine/threonine-protein kinase; PLF -proliferin; PRIP -PPAR-interacting protein; Prl2c2 -prolactin family 2, subfamily c, member 2; TNFa -tumor necrosis factor a; VEGF -vascular endothelial growth factor and PPARg facilitate the embryo implantation and placenta development through the effect on lipids, carbohydrates and amino-acids metabolism. Produced metabolites can be used by the fetus as substrates for energy metabolism, synthesis of the membranes and signaling molecules [110] . Interestingly, the fetal adaptations to the maternal diet might be regulated by two mechanisms. The first, short-term, mediated by PPARb and PPARg regulates cell growth and differentiation, while the second one, long-term, mediated by PPARa seems to be related to the epigenetic control of energy metabolism to optimize postnatal survival [110] . PPARa was also described as an important regulator of lipid catabolism in fetal liver and heart [111, 112] . An additional role of PPARs has been revealed during the development of embryonic nervous system. An activation of PPARg by natural agonists promoted neuronal differentiation in 17-day-old rat fetuses [113] . In addition, PPARb agonist prevented inflammation-induced neuronal death in microglia-neuron in in vitro co-cultures [114] . Based on the above results, it seems that PPARs play a significant role during the embryonic development. However, it has to be noted that general scarcity of data should encourage researchers to conduct studies in this field.
Conclusions
PPARs are expressed at different levels of hypothalamic-pituitary-gonadal axis. They are also present in the uterus as well as in the placenta and embryonic tissues of different species. Such an extensive distribution in the above tissues indicates an important role of PPARs in the regulation of various reproductive functions (Table 1) . Despite numerous studies concerning the expression and the role of PPARs in the modulation of female reproductive processes, several physiological and molecular properties of these receptors still remain unexplored. The understanding of the mechanisms that control the course of estrous/menstrual cycle, early pregnancy maintenance and gestation progress may contribute to an increase in the reproductive rates and improve economic parameters of farming animals. In addition, taking into consideration a fact, that certain PPAR ligands are used clinically to improve reproductive disorders, a precise understanding of PPARs' action in various reproductive tissues should be a significant reason for conducting more studies.
